Drug Trial Radar · NCT05029609
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Last checked: Nov 20, 2026Latest source record: Mar 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 2021
Primary completion
Nov 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Tiziana Life Sciences LTDIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses for 14 consecutive days.
Conditions
- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Multiple Sclerosis
Interventions
Intranasal Foralumab SolutionDrug
The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
PlaceboDrug
The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To establish the safety of intranasal foralumab in non-active primary and secondary progressive MS in escalating doses for 14 consecutive daysTime frame: 14 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.